Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1.

Smith KN, Llosa NJ, Cottrell TR, Siegel N, Fan H, Suri P, Chan HY, Guo H, Oke T, Awan AH, Verde F, Danilova L, Anagnostou V, Tam AJ, Luber BS, Bartlett BR, Aulakh LK, Sidhom JW, Zhu Q, Sears CL, Cope L, Sharfman WH, Thompson ED, Riemer J, Marrone KA, Naidoo J, Velculescu VE, Forde PM, Vogelstein B, Kinzler KW, Papadopoulos N, Durham JN, Wang H, Le DT, Justesen S, Taube JM, Diaz LA Jr, Brahmer JR, Pardoll DM, Anders RA, Housseau F.

J Immunother Cancer. 2019 Feb 11;7(1):40. doi: 10.1186/s40425-018-0492-x. Erratum in: J Immunother Cancer. 2019 Mar 6;7(1):63.

2.

Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.

Zhou G, Noordam L, Sprengers D, Doukas M, Boor PPC, van Beek AA, Erkens R, Mancham S, Grünhagen D, Menon AG, Lange JF, Burger PJWA, Brandt A, Galjart B, Verhoef C, Kwekkeboom J, Bruno MJ.

Oncoimmunology. 2018 Apr 25;7(7):e1448332. doi: 10.1080/2162402X.2018.1448332. eCollection 2018.

3.

The clinical utility of tumor mutational burden in non-small cell lung cancer.

Greillier L, Tomasini P, Barlesi F.

Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08. Review.

4.

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R.

Mol Cancer Ther. 2017 Nov;16(11):2598-2608. doi: 10.1158/1535-7163.MCT-17-0386. Epub 2017 Aug 23.

5.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

6.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.

PMID:
27137346
7.

Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer.

Czink E, Kloor M, Goeppert B, Fröhling S, Uhrig S, Weber TF, Meinel J, Sutter C, Weiss KH, Schirmacher P, Doeberitz MVK, Jäger D, Springfeld C.

Cold Spring Harb Mol Case Stud. 2017 Sep 1;3(5). pii: a001974. doi: 10.1101/mcs.a001974. Print 2017 Sep.

8.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Ma W, Gilligan BM, Yuan J, Li T.

J Hematol Oncol. 2016 May 27;9(1):47. doi: 10.1186/s13045-016-0277-y. Review.

9.

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.

Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB.

Neuro Oncol. 2017 Aug 1;19(8):1047-1057. doi: 10.1093/neuonc/nox026.

10.

Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.

Meng X, Huang Z, Teng F, Xing L, Yu J.

Cancer Treat Rev. 2015 Dec;41(10):868-76. doi: 10.1016/j.ctrv.2015.11.001. Epub 2015 Nov 10. Review.

PMID:
26589760
11.

Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.

Hendriks LE, Rouleau E, Besse B.

Transl Lung Cancer Res. 2018 Dec;7(6):647-660. doi: 10.21037/tlcr.2018.09.22. Review.

12.

Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.

Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, Tamragouri K, Rhee K, Mohindra N, Villaflor V, Park W, Lopes G, Giles FJ.

Oncologist. 2019 Mar 13. pii: theoncologist.2018-0433. doi: 10.1634/theoncologist.2018-0433. [Epub ahead of print]

PMID:
30867242
13.

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.

Fabrizio DA, George TJ Jr, Dunne RF, Frampton G, Sun J, Gowen K, Kennedy M, Greenbowe J, Schrock AB, Hezel AF, Ross JS, Stephens PJ, Ali SM, Miller VA, Fakih M, Klempner SJ.

J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.

14.

Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.

Sacher AG, Gandhi L.

JAMA Oncol. 2016 Sep 1;2(9):1217-22. doi: 10.1001/jamaoncol.2016.0639. Review.

PMID:
27310809
15.

Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?

Heeke S, Hofman P.

Transl Lung Cancer Res. 2018 Dec;7(6):631-638. doi: 10.21037/tlcr.2018.08.04. Review.

16.

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.

Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, Villaflor V, Giles F.

Clin Lung Cancer. 2019 Mar;20(2):88-96.e6. doi: 10.1016/j.cllc.2018.09.008. Epub 2018 Sep 25.

PMID:
30425022
17.

Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.

Wu SP, Liao RQ, Tu HY, Wang WJ, Dong ZY, Huang SM, Guo WB, Gou LY, Sun HW, Zhang Q, Xie Z, Yan LX, Su J, Yang JJ, Zhong WZ, Zhang XC, Wu YL.

J Thorac Oncol. 2018 Apr;13(4):521-532. doi: 10.1016/j.jtho.2017.11.132. Epub 2017 Dec 18.

PMID:
29269008
18.

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.

Goodman AM, Piccioni D, Kato S, Boichard A, Wang HY, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, Sicklick JK, Kurzrock R.

JAMA Oncol. 2018 Sep 1;4(9):1237-1244. doi: 10.1001/jamaoncol.2018.1701.

19.

Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?

Dempke WCM, Fenchel K, Dale SP.

Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S275-S279. doi: 10.21037/tlcr.2018.04.18.

20.

PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.

El Jabbour T, Ross JS, Sheehan CE, Affolter KE, Geiersbach KB, Boguniewicz A, Ainechi S, Bronner MP, Jones DM, Lee H.

J Clin Pathol. 2018 Jan;71(1):46-51. doi: 10.1136/jclinpath-2017-204525. Epub 2017 Jun 30.

PMID:
28667193

Supplemental Content

Support Center